Stay updated on SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check33 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check68 days agoChange DetectedThe web page has updated its date references, removing older dates from June 2023 and adding new dates in April 2025.SummaryDifference0.6%
- Check75 days agoChange DetectedThe web page has undergone significant updates, including the removal of detailed descriptions of a clinical trial for Head and Neck Squamous Cell Carcinoma (HNSCC) and the addition of a new version revision. Notably, the principal investigator's name and the collaborators have been retained.SummaryDifference53%
Stay in the know with updates to SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.